464 related articles for article (PubMed ID: 15231670)
1. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis.
Eckert LB; Repasky GA; Ulkü AS; McFall A; Zhou H; Sartor CI; Der CJ
Cancer Res; 2004 Jul; 64(13):4585-92. PubMed ID: 15231670
[TBL] [Abstract][Full Text] [Related]
2. K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1.
Sheng H; Shao J; Dubois RN
Cancer Res; 2001 Mar; 61(6):2670-5. PubMed ID: 11289146
[TBL] [Abstract][Full Text] [Related]
3. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
4. p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells.
Kim MS; Lee EJ; Kim HR; Moon A
Cancer Res; 2003 Sep; 63(17):5454-61. PubMed ID: 14500381
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase-dependent, phosphatidylinositol 3'-kinase, and mitogen-activated protein kinase-independent signaling pathways prevent lung adenocarcinoma cells from anoikis.
Wei L; Yang Y; Yu Q
Cancer Res; 2001 Mar; 61(6):2439-44. PubMed ID: 11289112
[TBL] [Abstract][Full Text] [Related]
6. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
7. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
[TBL] [Abstract][Full Text] [Related]
8. Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells.
Normanno N; De Luca A; Bianco C; Maiello MR; Carriero MV; Rehman A; Wechselberger C; Arra C; Strizzi L; Sanicola M; Salomon DS
J Cell Physiol; 2004 Jan; 198(1):31-9. PubMed ID: 14584041
[TBL] [Abstract][Full Text] [Related]
9. p21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase/PKB, mediated signaling pathways in T lymphocytes.
Genot E; Reif K; Beach S; Kramer I; Cantrell D
Oncogene; 1998 Oct; 17(13):1731-8. PubMed ID: 9796702
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
[TBL] [Abstract][Full Text] [Related]
12. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling.
Ravid D; Maor S; Werner H; Liscovitch M
Oncogene; 2005 Feb; 24(8):1338-47. PubMed ID: 15592498
[TBL] [Abstract][Full Text] [Related]
13. COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells.
Choi EM; Kwak SJ; Kim YM; Ha KS; Kim JI; Lee SW; Han JA
Exp Mol Med; 2005 Jun; 37(3):199-203. PubMed ID: 16000874
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R
Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
[TBL] [Abstract][Full Text] [Related]
16. Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways.
Choi JA; Park MT; Kang CM; Um HD; Bae S; Lee KH; Kim TH; Kim JH; Cho CK; Lee YS; Chung HY; Lee SJ
Oncogene; 2004 Jan; 23(1):9-20. PubMed ID: 14712206
[TBL] [Abstract][Full Text] [Related]
17. Human intestinal epithelial crypt cell survival and death: Complex modulations of Bcl-2 homologs by Fak, PI3-K/Akt-1, MEK/Erk, and p38 signaling pathways.
Harnois C; Demers MJ; Bouchard V; Vallée K; Gagné D; Fujita N; Tsuruo T; Vézina A; Beaulieu JF; Côté A; Vachon PH
J Cell Physiol; 2004 Feb; 198(2):209-22. PubMed ID: 14603523
[TBL] [Abstract][Full Text] [Related]
18. Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1.
Demers MJ; Thibodeau S; Noël D; Fujita N; Tsuruo T; Gauthier R; Arguin M; Vachon PH
J Cell Biochem; 2009 Jul; 107(4):639-54. PubMed ID: 19479902
[TBL] [Abstract][Full Text] [Related]
19. Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways.
Bouchard V; Demers MJ; Thibodeau S; Laquerre V; Fujita N; Tsuruo T; Beaulieu JF; Gauthier R; Vézina A; Villeneuve L; Vachon PH
J Cell Physiol; 2007 Sep; 212(3):717-28. PubMed ID: 17443665
[TBL] [Abstract][Full Text] [Related]
20. Activation of the Ral and phosphatidylinositol 3' kinase signaling pathways by the ras-related protein TC21.
Rosário M; Paterson HF; Marshall CJ
Mol Cell Biol; 2001 Jun; 21(11):3750-62. PubMed ID: 11340168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
